Teleflex’ QuikClot Control+ Hemostatic Device Receives the US FDA’s Clearance for Expanded Indication in Cardiac Surgical Procedures
Shots:
- The US FDA has cleared the QuikClot Control+ Hemostatic device to include mild and mod. bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy
- Patients on anticoagulant or antiplatelet medication can now utilize the device. It may be utilized with/out cardiopulmonary bypass systems and can treat patients with/out autotransfusion equipment.
- The results published in JTCVS Open showed superiority for the QuikClot Control+ Hemostatic device over standard gauze with no difference in safety outcomes. Patients receiving the hemostatic device achieved hemostasis at ≥20% higher proportion at 5 & 10min. intervals
Ref: Massdevice | Image: Teleflex
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
